| Evolocumab and clinical outcomes in patients with cardiovascular disease MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ... New England journal of medicine 376 (18), 1713-1722, 2017 | 5557 | 2017 |
| Canagliflozin and renal outcomes in type 2 diabetes and nephropathy V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ... New England journal of medicine 380 (24), 2295-2306, 2019 | 4951 | 2019 |
| Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study K Swedberg, M Komajda, M Böhm, JS Borer, I Ford, A Dubost-Brama, ... The Lancet 376 (9744), 875-885, 2010 | 3316 | 2010 |
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes WB White, CP Cannon, SR Heller, SE Nissen, RM Bergenstal, GL Bakris, ... New England journal of medicine 369 (14), 1327-1335, 2013 | 3092 | 2013 |
| Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial K Fox, I Ford, PG Steg, M Tendera, R Ferrari The Lancet 372 (9641), 807-816, 2008 | 1463 | 2008 |
| Tiotropium versus salmeterol for the prevention of exacerbations of COPD C Vogelmeier, B Hederer, T Glaab, H Schmidt, MPMH Rutten-van Mölken, ... New England Journal of Medicine 364 (12), 1093-1103, 2011 | 958 | 2011 |
| Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial F Zannad, CP Cannon, WC Cushman, GL Bakris, V Menon, AT Perez, ... The Lancet 385 (9982), 2067-2076, 2015 | 871 | 2015 |
| Rivaroxaban for thromboprophylaxis in acutely ill medical patients AT Cohen, TE Spiro, HR Büller, L Haskell, D Hu, R Hull, A Mebazaa, ... New England Journal of Medicine 368 (6), 513-523, 2013 | 727 | 2013 |
| Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors MR Weir, GL Bakris, DA Bushinsky, MR Mayo, D Garza, Y Stasiv, J Wittes, ... New England Journal of Medicine 372 (3), 211-221, 2015 | 678 | 2015 |
| Ivabradine in stable coronary artery disease without clinical heart failure K Fox, I Ford, PG Steg, JC Tardif, M Tendera, R Ferrari New England Journal of Medicine 371 (12), 1091-1099, 2014 | 618 | 2014 |
| Darapladib for preventing ischemic events in stable coronary heart disease Stability Investigators New England Journal of Medicine 370 (18), 1702-1711, 2014 | 551 | 2014 |
| EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study KK Ray, B Molemans, WM Schoonen, P Giovas, S Bray, G Kiru, J Murphy, ... European journal of preventive cardiology 28 (11), 1279-1289, 2021 | 536 | 2021 |
| Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure JR Teerlink, R Diaz, GM Felker, JJV McMurray, M Metra, SD Solomon, ... New England Journal of Medicine 384 (2), 105-116, 2021 | 528 | 2021 |
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial K Strojek, KH Yoon, V Hruba, M Elze, AM Langkilde, S Parikh Diabetes, Obesity and Metabolism 13 (10), 928-938, 2011 | 528 | 2011 |
| Tiotropium Respimat inhaler and the risk of death in COPD RA Wise, A Anzueto, D Cotton, R Dahl, T Devins, B Disse, D Dusser, ... New England Journal of Medicine 369 (16), 1491-1501, 2013 | 464 | 2013 |
| Эндотелиальная дисфункция при патологии сердечно-сосудистой системы ЛТ Малая, АН Корж, ЛБ Балковая Харьков: Торсинг 432, 2000 | 452 | 2000 |
| Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 KL Ong, LK Stafford, SA McLaughlin, EJ Boyko, SE Vollset, AE Smith, ... The Lancet 402 (10397), 203-234, 2023 | 435 | 2023 |
| Triglyceride lowering with pemafibrate to reduce cardiovascular risk A Das Pradhan, RJ Glynn, JC Fruchart, JG MacFadyen, ES Zaharris, ... New England Journal of Medicine 387 (21), 1923-1934, 2022 | 317 | 2022 |
| Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial WW Busse, ER Bleecker, JM FitzGerald, GT Ferguson, P Barker, ... The lancet respiratory medicine 7 (1), 46-59, 2019 | 283 | 2019 |
| Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups: results … KW Mahaffey, MJ Jardine, S Bompoint, CP Cannon, B Neal, ... Circulation 140 (9), 739-750, 2019 | 264 | 2019 |
